JP2019006815A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019006815A5 JP2019006815A5 JP2018173770A JP2018173770A JP2019006815A5 JP 2019006815 A5 JP2019006815 A5 JP 2019006815A5 JP 2018173770 A JP2018173770 A JP 2018173770A JP 2018173770 A JP2018173770 A JP 2018173770A JP 2019006815 A5 JP2019006815 A5 JP 2019006815A5
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- mole
- peg
- chol
- liposome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 22
- -1 phosphatidyl choline lipid Chemical class 0.000 claims 19
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 18
- 229940123237 Taxane Drugs 0.000 claims 12
- 239000002502 liposome Substances 0.000 claims 12
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 11
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 10
- 235000012000 cholesterol Nutrition 0.000 claims 9
- 229930182558 Sterol Natural products 0.000 claims 8
- 150000003432 sterols Chemical class 0.000 claims 8
- 235000003702 sterols Nutrition 0.000 claims 8
- 150000002632 lipids Chemical class 0.000 claims 7
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 7
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 6
- 229920001223 polyethylene glycol Polymers 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 5
- 239000000232 Lipid Bilayer Substances 0.000 claims 4
- 125000001589 carboacyl group Chemical group 0.000 claims 3
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 2
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 claims 2
- ATHVAWFAEPLPPQ-VRDBWYNSSA-N 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC ATHVAWFAEPLPPQ-VRDBWYNSSA-N 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- JCXZKUZXVQKENT-UHFFFAOYSA-N 2-(4-methylpiperazin-1-ium-1-yl)acetate Chemical compound CN1CCN(CC(O)=O)CC1 JCXZKUZXVQKENT-UHFFFAOYSA-N 0.000 claims 1
- VRDBIJCCXDEZJN-UHFFFAOYSA-N 2-piperidin-1-ylacetic acid Chemical compound OC(=O)CN1CCCCC1 VRDBIJCCXDEZJN-UHFFFAOYSA-N 0.000 claims 1
- JSHLMMUXJIDENZ-UHFFFAOYSA-N 3-(4-methylpiperazin-1-ium-1-yl)propanoate Chemical compound CN1CCN(CCC(O)=O)CC1 JSHLMMUXJIDENZ-UHFFFAOYSA-N 0.000 claims 1
- YUYHRSGXZZVNMS-UHFFFAOYSA-N 3-morpholin-4-ylpropanoic acid Chemical compound OC(=O)CCN1CCOCC1 YUYHRSGXZZVNMS-UHFFFAOYSA-N 0.000 claims 1
- LPDGWMLCUHULJF-UHFFFAOYSA-N 3-piperidin-1-ylpropanoic acid Chemical compound OC(=O)CCN1CCCCC1 LPDGWMLCUHULJF-UHFFFAOYSA-N 0.000 claims 1
- ATSKLAVSYMLSEX-UHFFFAOYSA-N 4-(4-methylpiperazin-1-ium-1-yl)butanoate Chemical compound CN1CCN(CCCC(O)=O)CC1 ATSKLAVSYMLSEX-UHFFFAOYSA-N 0.000 claims 1
- PNHMBKXVXNJADT-UHFFFAOYSA-N 4-morpholin-4-ium-4-ylbutanoate Chemical compound OC(=O)CCCN1CCOCC1 PNHMBKXVXNJADT-UHFFFAOYSA-N 0.000 claims 1
- BGAVZPPPWLEAKZ-UHFFFAOYSA-N 4-piperidin-1-ylbutanoic acid Chemical compound OC(=O)CCCN1CCCCC1 BGAVZPPPWLEAKZ-UHFFFAOYSA-N 0.000 claims 1
- AROMGYXEPCNUQL-UHFFFAOYSA-N 5-(4-methylpiperazin-1-ium-1-yl)pentanoate Chemical compound CN1CCN(CCCCC(O)=O)CC1 AROMGYXEPCNUQL-UHFFFAOYSA-N 0.000 claims 1
- BSVYXFWQDRWOFH-UHFFFAOYSA-N 5-morpholin-4-ylpentanoic acid Chemical compound OC(=O)CCCCN1CCOCC1 BSVYXFWQDRWOFH-UHFFFAOYSA-N 0.000 claims 1
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 claims 1
- VIWZVFVJPXTXPA-UHFFFAOYSA-N N-(2-Carboxymethyl)-morpholine Chemical compound OC(=O)CN1CCOCC1 VIWZVFVJPXTXPA-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Natural products CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims 1
- 235000011130 ammonium sulphate Nutrition 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 150000008105 phosphatidylcholines Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779902P | 2013-03-13 | 2013-03-13 | |
| US61/779,902 | 2013-03-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017177620A Division JP2017214433A (ja) | 2013-03-13 | 2017-09-15 | 修飾されたドセタキセルリポソーム製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019006815A JP2019006815A (ja) | 2019-01-17 |
| JP2019006815A5 true JP2019006815A5 (enExample) | 2019-07-25 |
Family
ID=50686145
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502155A Expired - Fee Related JP6294456B2 (ja) | 2013-03-13 | 2014-03-13 | 修飾されたドセタキセルリポソーム製剤 |
| JP2017177620A Pending JP2017214433A (ja) | 2013-03-13 | 2017-09-15 | 修飾されたドセタキセルリポソーム製剤 |
| JP2018173770A Pending JP2019006815A (ja) | 2013-03-13 | 2018-09-18 | 修飾されたドセタキセルリポソーム製剤 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502155A Expired - Fee Related JP6294456B2 (ja) | 2013-03-13 | 2014-03-13 | 修飾されたドセタキセルリポソーム製剤 |
| JP2017177620A Pending JP2017214433A (ja) | 2013-03-13 | 2017-09-15 | 修飾されたドセタキセルリポソーム製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20140271822A1 (enExample) |
| EP (1) | EP2968145A1 (enExample) |
| JP (3) | JP6294456B2 (enExample) |
| CN (1) | CN105188675A (enExample) |
| BR (1) | BR112015022819A8 (enExample) |
| CA (1) | CA2903255C (enExample) |
| MX (1) | MX2015012201A (enExample) |
| WO (1) | WO2014160392A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140271822A1 (en) * | 2013-03-13 | 2014-09-18 | Mallinckrodt Llc | Modified docetaxel liposome formulations |
| CN104622810B (zh) * | 2015-02-15 | 2018-06-08 | 中国药科大学 | 一种稳定型难溶性抗肿瘤药物脂质体及其制备方法 |
| WO2016134066A1 (en) * | 2015-02-17 | 2016-08-25 | Mallinckrodt Llc | Modified docetaxel liposome formulations and uses thereof |
| WO2016161428A1 (en) * | 2015-04-02 | 2016-10-06 | The Research Foundation For The State University Of New York | Serum-stable compositions and methods for light-triggered release of materials |
| WO2017053464A1 (en) * | 2015-09-21 | 2017-03-30 | Mallinckrodt Llc | Improved stability of liposome formulations and uses thereof |
| PE20181445A1 (es) * | 2016-01-07 | 2018-09-12 | Univ Western Health Sciences | Formulaciones para el tratamiento del cancer de vejiga |
| CA3016383A1 (en) * | 2016-03-16 | 2017-09-21 | Merrimack Pharmaceuticals, Inc | Treating ephrin receptor a2 (epha2) positive cancer with targeted docetaxel-generating nano-liposome compositions |
| JP2019508434A (ja) * | 2016-03-16 | 2019-03-28 | メリマック ファーマシューティカルズ インコーポレーティッド | エフリン受容体A2(EphA2)標的ドセタキセル産生ナノリポソーム組成物 |
| CN108883199A (zh) * | 2016-03-16 | 2018-11-23 | 梅里麦克制药股份有限公司 | 肝配蛋白受体a2(epha2)的纳米脂质体靶向和相关诊断 |
| JP7079250B2 (ja) * | 2016-08-18 | 2022-06-01 | ブレマー,トロイ | リポソーム構築物を用いた黄斑細胞及び網膜細胞への尿素の送達 |
| CN107951861B (zh) * | 2016-10-17 | 2020-12-01 | 南京绿叶制药有限公司 | 一种脂质纳米粒膜材料组合物 |
| US20210290537A1 (en) * | 2016-12-08 | 2021-09-23 | Mallinckrodt Llc | Liposomal elinafide formulations and uses thereof |
| KR20200049759A (ko) | 2017-07-07 | 2020-05-08 | 드렉셀유니버시티 | 전압-활성화 치료, 진단, 및/또는 치료진단 컨스트럭트 |
| CN110496103B (zh) * | 2018-05-18 | 2022-05-10 | 上海维洱生物医药科技有限公司 | 一种多西他赛棕榈酸酯脂质体及其制备方法 |
| JP7482487B2 (ja) * | 2018-09-13 | 2024-05-14 | タイワン リポソーム カンパニー リミテッド | 鎮静薬を含む徐放性医薬組成物およびその使用 |
| US12274785B2 (en) | 2018-10-17 | 2025-04-15 | Taiwan Liposome Co., Ltd. | Sustained-release pharmaceutical compositions comprising an immunomodulating agent and uses thereof |
| KR20220054318A (ko) * | 2019-08-09 | 2022-05-02 | 테소륵스 파마, 엘엘씨 | 프로리포솜성 테스토스테론 운데카노에이트 제형 |
| CN110571005B (zh) * | 2019-09-27 | 2021-01-01 | 广西科技大学 | 一种固定化金属离子-磁性脂质体及其制备方法和应用 |
| CN111004195B (zh) * | 2019-12-03 | 2022-01-28 | 沈阳药科大学 | 卡巴他赛弱碱性衍生物及其制剂 |
| CN114588279B (zh) * | 2022-03-31 | 2023-10-20 | 重庆医科大学附属第二医院 | 一种多功能纳米分子探针及其制备方法和其作为视网膜母细胞瘤诊疗制剂的应用 |
| WO2025124498A1 (zh) * | 2023-12-13 | 2025-06-19 | 上海艾力斯医药科技股份有限公司 | 一种含氮杂环化合物的脂质体及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994005282A1 (en) | 1992-09-04 | 1994-03-17 | The Scripps Research Institute | Water soluble taxol derivatives |
| US5824701A (en) | 1993-10-20 | 1998-10-20 | Enzon, Inc. | Taxane-based prodrugs |
| US6107332A (en) | 1995-09-12 | 2000-08-22 | The Liposome Company, Inc. | Hydrolysis-promoting hydrophobic taxane derivatives |
| TW520297B (en) * | 1996-10-11 | 2003-02-11 | Sequus Pharm Inc | Fusogenic liposome composition and method |
| US6541508B2 (en) | 1999-09-13 | 2003-04-01 | Nobex Corporation | Taxane prodrugs |
| CA2383259A1 (en) * | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
| AU2003287526A1 (en) * | 2002-11-06 | 2004-06-03 | Protein-stabilized liposomal formulations of pharmaceutical agents | |
| US20070003607A1 (en) * | 2003-09-02 | 2007-01-04 | Vibhudutta Awasthi | Neutral liposome-encapsulated compounds and methods of making and using thereof |
| EP1809246B1 (en) * | 2004-10-08 | 2008-07-16 | Alza Corporation | Method of insertion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves |
| MX2007013200A (es) * | 2005-04-22 | 2008-03-24 | Johnson & Johnson | Composicion de inmunoliposoma para el direccionamiento hacia un receptor de la celula her2. |
| CN101485629B (zh) * | 2008-01-16 | 2013-01-23 | 沈阳药科大学 | 一种给药系统及其制备方法 |
| US8790691B2 (en) * | 2008-05-23 | 2014-07-29 | The University Of British Columbia | Modified drugs for use in liposomal nanoparticles |
| CN102038641B (zh) * | 2009-10-26 | 2013-04-17 | 石药集团中奇制药技术(石家庄)有限公司 | 一种外层经亲水聚合物修饰的脂质体药物的制备方法 |
| US20120231066A1 (en) * | 2011-01-24 | 2012-09-13 | Henry John Smith | Multi-drug liposomes to treat tumors |
| JP2014503582A (ja) * | 2011-01-28 | 2014-02-13 | コーニンクレッカ フィリップス エヌ ヴェ | 親水性プロドラッグの局所放出用担体 |
| CN102188713A (zh) * | 2011-05-09 | 2011-09-21 | 中山大学 | 一种肝靶向药物组合物及其制备方法 |
| US20140271822A1 (en) * | 2013-03-13 | 2014-09-18 | Mallinckrodt Llc | Modified docetaxel liposome formulations |
-
2014
- 2014-03-13 US US14/208,324 patent/US20140271822A1/en not_active Abandoned
- 2014-03-13 CA CA2903255A patent/CA2903255C/en not_active Expired - Fee Related
- 2014-03-13 JP JP2016502155A patent/JP6294456B2/ja not_active Expired - Fee Related
- 2014-03-13 MX MX2015012201A patent/MX2015012201A/es unknown
- 2014-03-13 CN CN201480026436.6A patent/CN105188675A/zh active Pending
- 2014-03-13 BR BR112015022819A patent/BR112015022819A8/pt not_active IP Right Cessation
- 2014-03-13 EP EP14722857.1A patent/EP2968145A1/en not_active Withdrawn
- 2014-03-13 WO PCT/US2014/026483 patent/WO2014160392A1/en not_active Ceased
-
2017
- 2017-09-15 JP JP2017177620A patent/JP2017214433A/ja active Pending
-
2018
- 2018-09-18 JP JP2018173770A patent/JP2019006815A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019006815A5 (enExample) | ||
| AU2005281352B2 (en) | Liposomal compositions of glucocorticoid and glucocorticoid derivatives | |
| JP2020510072A5 (enExample) | ||
| US20170273906A1 (en) | Targeted liposomes encapsulating iron complexes and their uses | |
| RU2014120216A (ru) | Комбинационные липосомальные композиции для лечения рака | |
| CN101991538B (zh) | 一种含tpgs的脂质体组合物及其应用 | |
| PT2508170E (pt) | Lipossoma de irinotecano ou o seu cloridrato e seu método de preparação | |
| CA2739822A1 (en) | Liposomal systems comprising sphingomyelin | |
| WO2005117878A1 (ja) | イリノテカン製剤 | |
| JP7770367B2 (ja) | 徐放性麻酔剤組成物およびその調製方法 | |
| JP2016513651A5 (enExample) | ||
| JPWO2020071349A1 (ja) | 薬物を内包するリポソーム組成物およびプラチナ製剤を含む組合せ医薬 | |
| JP2018527335A5 (enExample) | ||
| TWI767133B (zh) | 含有治療憂鬱症或焦慮症之治療劑的緩釋組合物及其用途 | |
| JP6230538B2 (ja) | 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法 | |
| WO2013146386A1 (ja) | 局所麻酔薬持続性徐放製剤 | |
| JP2009513621A (ja) | リポソームを調製する方法及びその使用 | |
| JP4833836B2 (ja) | リポソーム製剤 | |
| WO2023288100A1 (en) | Liposomal formulations of bcl inhibitors | |
| WO2006027785A1 (en) | Liposomal formulations comprising an amphipathic weak base like tempamine for treatment of neurodegenerative conditions | |
| WO2000009071A2 (en) | A novel liposomal formulation useful in treatment of cancer and other proliferation diseases | |
| AU2016233143B2 (en) | Methods for the treatment of bladder cancer | |
| JP2024526800A (ja) | Bcl阻害剤のリポソーム製剤 |